Literature DB >> 10490956

Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression.

M Delgado1, J Leceta, R P Gomariz, D Ganea.   

Abstract

Vasoactive intestinal peptide (VIP) and the pituitary adenylate cyclase-activating polypeptide (PACAP), two structurally related neuropeptides produced within the lymphoid microenvironment, modulate several immunologic functions. We have recently demonstrated that VIP and PACAP enhance the macrophage costimulatory activity for naive CD4+ T cells exposed to allogeneic or anti-CD3 stimuli through the differential regulation of the B7 costimulatory molecules. In this study, we report on the role of VIP and PACAP on macrophage B7 expression and costimulatory function for Ag-primed CD4+ T cells, and on the macrophage-induced regulation of Th1/Th2 differentiation in vitro and in vivo. VIP and PACAP up-regulate the costimulatory activity of macrophages for Ag-primed CD4+ T cells. VIP-/PACAP-treated macrophages gain the ability to induce Th2-type cytokines such as IL-4 and IL-5 and reduce Th1-type cytokines such as IFN-gamma and IL-2. In vivo administration of VIP or PACAP in Ag-immunized mice reduce the numbers of IFN-gamma-secreting cells and enhance the numbers of IL-4-secreting cells. One of the consequences of the VIP-/PACAP-induced shift in cytokine profile is a change in the Ag-specific Ig isotype, increasing IgG1 and decreasing IgG2a levels. Finally, the preferential differentiation into Th2 effector cells after Ag stimulation induced by VIP-/PACAP-treated macrophages is mediated through the up-regulation of B7.2 expression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10490956

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

1.  Administration of a vasoactive intestinal peptide antagonist enhances the autologous anti-leukemia T cell response in murine models of acute leukemia.

Authors:  Christopher T Petersen; Jian-Ming Li; Edmund K Waller
Journal:  Oncoimmunology       Date:  2017-03-16       Impact factor: 8.110

Review 2.  Without nerves, immunology remains incomplete -in vivo veritas.

Authors:  Andrew J Shepherd; James E G Downing; Jaleel A Miyan
Journal:  Immunology       Date:  2005-10       Impact factor: 7.397

3.  Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses.

Authors:  Elena Gonzalez-Rey; Amelia Fernandez-Martin; Alejo Chorny; Javier Martin; David Pozo; Doina Ganea; Mario Delgado
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

4.  Vasoactive intestinal polypeptide suppressed experimental autoimmune encephalomyelitis by inhibiting T helper 1 responses.

Authors:  Haiyan Li; Yunhua Mei; Ying Wang; Lingyun Xu
Journal:  J Clin Immunol       Date:  2006-09-10       Impact factor: 8.317

5.  Pituitary adenylate cyclase-activating peptide and vasoactive intestinal polypeptide bias Langerhans cell Ag presentation toward Th17 cells.

Authors:  Wanhong Ding; Michela Manni; Lori L Stohl; Xi K Zhou; John A Wagner; Richard D Granstein
Journal:  Eur J Immunol       Date:  2012-04       Impact factor: 5.532

6.  Adrenomedullin protects from experimental arthritis by down-regulating inflammation and Th1 response and inducing regulatory T cells.

Authors:  Elena Gonzalez-Rey; Alejo Chorny; Francisco O'Valle; Mario Delgado
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

7.  Impaired nerve regeneration and enhanced neuroinflammatory response in mice lacking pituitary adenylyl cyclase activating peptide.

Authors:  B D Armstrong; C Abad; S Chhith; G Cheung-Lau; O E Hajji; H Nobuta; J A Waschek
Journal:  Neuroscience       Date:  2007-10-30       Impact factor: 3.590

8.  A novel VIP signaling pathway in T cells cAMP-->protein tyrosine phosphatase (SHP-2?)-->JAK2/STAT4-->Th1 differentiation.

Authors:  Li Liu; Jui-Hung Yen; Doina Ganea
Journal:  Peptides       Date:  2007-03-31       Impact factor: 3.750

9.  Protected graft copolymer excipient leads to a higher acute maximum tolerated dose and extends residence time of vasoactive intestinal Peptide significantly better than sterically stabilized micelles.

Authors:  Sandra Reichstetter; Gerardo M Castillo; Israel Rubinstein; Akiko Nishimoto-Ashfield; Manshun Lai; Cynthia C Jones; Aryamitra A Banerjee; Aryamitra Banjeree; Alex Lyubimov; Duane C Bloedow; Alexei Bogdanov; Elijah M Bolotin
Journal:  Pharm Res       Date:  2012-12-07       Impact factor: 4.200

10.  Proinflammatory tachykinins that signal through the neurokinin 1 receptor promote survival of dendritic cells and potent cellular immunity.

Authors:  Brian M Janelsins; Alicia R Mathers; Olga A Tkacheva; Geza Erdos; William J Shufesky; Adrian E Morelli; Adriana T Larregina
Journal:  Blood       Date:  2008-11-05       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.